Literature DB >> 36155899

Update meta-analysis from biomedical literature about MTHFR'polymorphisms and the CML' risk.

Fatma Turki, Nour Louati, Hassen Kamoun, Leila Keskes, Tarek Rebaii, Rim Frikha.   

Abstract

BACKGROUND: The MTHFR gene polymorphisms are closely related to the chronic myeloid leukemia (CML). Case-control studies have associated the MTHFR polymorphisms and susceptibility to CML but the results were not conclusive. AIM: To assess this association through an update meta-analysis.
METHODS: A descriptive and qualitative study was conducted among students in the 6th year of the faculty during the academic year 2020/2021. The data were collected through a questionnaire written in french evaluating the teaching methods. A focus group of ten persons was led to understand better student's opinions.
RESULTS: Totally, 17 and 12 case-control studies including CML cases and controls were enrolled in the meta-analysis respectively for C677T and A1298C polymorphism and CML risk. A poor association between the C677T (T vs C ; OR= 1,28; IC95%= [1,01;1,63]; p=0,04) and the one not significant between the A1298C (C vs A ; OR= 1,52; IC95%= [0,92; 2,51]; p= 0,1) polymorphisms and the CML risk for overall population were found.
CONCLUSION: The results of this meta-analysis suggested no significant association between C677T and A1298C polymorphisms and CML risk leading to consider other factors such us folic acid intake, gene-gene and gene- environment interactions.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 36155899      PMCID: PMC9476263     

Source DB:  PubMed          Journal:  Tunis Med        ISSN: 0041-4131


INTRODUCTION:

The cause of human cancer is a consequence of complex interplay between genetic predisposition and environmental factors. Susceptibility to different types of leukemia seems to be related to polymorphisms in multiple genes and various genetic events during blood cell development(1 ). Chronic myelogenous leukemia (CML), an example treated in this meta-analysis, is a myeloproliferative disease characterized by the reciprocal translocation t (9; 22) (q34; q11) and bcr-abl fusion transcript(2 ). It’s a common malignancy of hematopoietic stem cells distinguished by an abnormal accumulation of white blood cells in the bone marrow that interferes with the normal production of blood cells. Since the introduction of Imatinib in 2000, the annual mortality in CML has decreased from 10%-20% down to 1%-2% (3, 4 ). Clinical and biological aspects of CML are well investigated, but the factors that cause individuals ’ susceptibilities to CML are still not fully understood(3 ). Assessment of causes of CML may be beneficial for clinical management and prevention. CML are likely to be affected by the metabolic fate of folic acid(5 ). Folate methylation plays an essential role in DNA synthesis and methylation processes(6 ). Folate deficiency have been associated with hypomethylation and uracil mis-incorporation into DNA during replication, increasing the risk of chromosomal aberrations and facilitating the onset of oncogenic processes(7 ). Folate metabolism requires the optimal activity of various enzymes(8 ). 5, 10 methylene tetrahydrofolate reductase (MTHFR) is one of the important enzymes of the folate cycles(9 ). It irreversibly reduces 5, 10 methylene tetrahydrofolate to 5 methyl tetrahydrofolate, the primary form of serum folate and carbon donor for the remethylation of homocysteine to methionine(10 ). The MTHFR gene is located on the short arm of chromosome 1(1p36.3). There are two commonly occurring polymorphisms in the MTHR gene: C677T and A1298C. C677T occurs in exon 4 and results in alanine to valine substitution at codon 222, while a second common polymorphism, A1298C in exon 7, results in a glutamate to alanine substitution at codon 429(11 ). To date, several studies performed in different countries have assessed the association between MTHFR’ polymorphisms and susceptibility to malignant hemopathies like acute lymphoblastic leukemia (12 ) and CML. But, the results were inconclusive and conflicting (13, 14 ). Moreover, the previous meta-analyses had limited sample sizes and so the statistical study still not powerful to demonstrate a significant association (15, 16, 17 ). Therefore, we carried out our meta-analysis which will be the most exhaustive in order to determine the relationship between the MTHFR polymorphisms and the risk of development of CML according to the models and the ethnicity.

METHODES :

Search strategy:

A comprehensive search that investigated the association between the MTHFR C677T or A1298C genetic variants and the risk of adult CML published before June 2018 was conducted in PubMed electronic databases. The following combined descriptor terms were used: (« Methylenetetrahydrofolate reductase » OR « MTHFR ») AND (« Chronic myeloid leukemia »). The search included only journal articles. All references cited in the studies were extensively reviewed to identify additional published articles.

Studies selection :

Published studies before June 2018; were selected in the analysis according to these following inclusion criteria: (1 ) case-control study; (2 ) study evaluating the association between C677T and A1298C polymorphisms and susceptibility to CML; and (3 ) study presenting available data on the distribution of MTHFR gene polymorphisms in cases and in control groups which are sufficient for calculating odds ratio. For multiple studies using the same groups of patients or controls, the study with the largest sample size was included in the meta-analysis. We excluded articles which are reviews and not publications. Data of Meta-analyses which are also excluded will be used for comparison and discussion later. As a whole, this meta-analysis was carried out according to the preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA).

Data extraction :

Two independent investigators checked each report and extracted and tabulated the following data from eligible studies: name of the first author, year of publication, country of origin, ethnicity of the study population, numbers and genotype distributions of cases and controls.

Statistical analysis :

The meta-analysis, using the software http://bioinfo.genyo.es/metagenyo/ (18 ), examined different genetic comparison models namely allele contrast model (« T vs. C » or  « C vs. A »), recessive model (« CC+CT vs. TT » or « AA+AC vs. CC »), dominant model (« TT+TC vs. CC » or « CC+AC vs. AA »), homozygote model (« TT vs. CC » or « CC vs. AA ») and heterozygote model (« CT vs. CC » or « AC vs. AA ») for estimation of the association between MTHFR C677T and/or A1298C polymorphisms and CML risk, respectively. The genotype distribution was assessed for Hardy-Weinberg Equilibrium (HWE) to check study quality, P(HWE)< 0,05 showed statistical significance and so control genotype might not be in HWE and should be excluded from the meta-analysis (18 ). The odds ratio (OR) and 95% confidence interval (CI) were calculated using data for genotype distribution. These association tests results evaluated the association’ strength between MTHFR polymorphisms and CML risks. If the value 1 was not in the range of CI, it was considered that there is an increased relative risk in one group compared with the other (18 ). The heterogeneity was determined by calculating I² metric statistic. I²<25%, 25%50% were interpreted as low, moderate, and high degrees of heterogeneity, respectively (19 ). When no heterogeneity was found with p >0, 05 or I² < 50%, a fixed effect model was chosen to estimate the pooled ORs with their corresponding 95%CIs. Otherwise, a random-effects model was used (20 ). Forest plots were provided by the meta-analysis to estimate the global result of all studies. Funnel plot, a graphical test, was used to check if publication bias exists or not. So asymmetry of the funnel plot suggested a possible publication bias. The Egger’s test could be used ; p<0,05 was considered as a potential statistical publication bias(21 ). Subgroup analysis also was performed according to the ethnicities. Sensitivity analyses were conducted to examine whether the individual study influenced the pooled results.

RESULTS :

Search of published reports :

A flow chart depicting the study selection process is shown in Figure 1.

Figure. 1. Flow diagram for study inclusion in the meta-analysis and reasons for study exclusion

.26 articles were identified based on various combinations of the keywords listed in the Methods and focused on the relationship between MTHFR gene SNPs and the risk of CML. On these articles, 9 were reviews and 3 were meta-analyses. Therefore, only 17 studies qualified for inclusion in this meta-analysis.

Study characteristics:

Characteristics of the 17 articles included in the meta-analysis were shown in Table 1, Table 2 . The studies were conducted in various populations of different ethnicities, as Asian (6 studies), Caucasian (5 studies), Mixed (5 studies) and one on African population for MTHFR C677T polymorphism. However, the A1298C polymorphism was distributed in 4, 2, 1 and 5 studies for Asian, Caucasian, African and Mixed population respectively.

Table 1. Study characteriscs : Publication year ; ethnicity ; polymorphisms studied; number and mean age of both cases and controls

First author

Publication year

Ethnicity (country)

Polymorphisms studied

Cases

Controles

Number

Mean Age (years)

Number

Mean Age (years)

Deligezer 2003(25 )

2003

Caucasian (Turkey)

C677T

131 (F/M= 70/61)

45,9

161 (F/M= 112/48)

39

Hur 2006(22 )

2006

Asian (Korea)

C677T, A1298C

40 (F/M= 13/27)

50

200 (F/M= 72/128

34

Chen 2006(6)

2006

Asian (China)

C677T

7 (NA)

NA

157 (NA)

NA

Moon 2007(26 )

2007

Asian (Korea)

C677T, A1298C

115 (F/M= 40/75)

43,8

434 (F/M=238/19)

41,4

Barbosa(7)

2008

Mixed (Brasil)

C677T, A1298C

67 (F/M= 30/36)

44

100 (F/M=47/53)

29

Kim 2009(27 )

2009

Asian (Korea)

C677T, A1298C

149 (F/M= 55/94)

50,4

1700 (F/M= 879/821)

52,2

Ismail 2008(28 )

2009

Mixed (Jordan)

C677T, A1298C

149 (NA)

NA

170 (NA)

NA

Vahid 2010(23 )

2010

Mixed (Iran)

C677T, A1298C

38 (F/M= 19/19)

45

97(F/M= 50/47)

44,8

Jankovic 2011(29 )

2011

Caucasian (Serbia)

C677T

43 (NA)

NA

26 (NA)

NA

Lordelo 2012(24 )

2012

Caucasian

C677T, A1298C

41 (NA)

NA

155 (NA)

NA

Lordelo 2012(24 )

2012

Mixed (Brasil)

C677T, A1298C

64 (NA)

NA

118 (NA)

NA

Hussein 2012(30 )

2012

Asian (India)

C677T

43 (NA)

39,5

251 (NA)

41,5

Jakoljevic 2013(31 )

2012

Caucasian (Serbia)

C677T

52 (F/M= 24/28)

NA

53 (F/M= 24/30)

NA

Dorgham 2014(32 )

2014

African (Algeria)

C677T, A1298C

90 (NA)

45,9

100 (NA)

47,3

Banescu 2014(33 )

2014

Caucasian (Romania)

C677T, A1298C

151 (F/M= 65/86)

51

305 (F/M= 179/126)

47

Rabab M Aly 2014(14)

2014

Mixed (Egypt)

C677T, A1298C

85 (F/M= 40/45)

46,7

100 (F/M= 49/51)

48,2

Korshied 2014(13 )

2014

MIxed (Egypt)

C677T, A1298C

97 (F/M= 51/46)

NA

130 (F/M= 68/62)

NA

F: female; M: male; NA: not available

Table 2

Table 2. Distribution of MTHFR C677T and A1298C genotypes in cases and controls and calculation of P value.

Study

Distribution of C677T MTHFR genotype(n)

HWE P value

Distribution of A1298 MTHFR genotype(n)

HWE P value

Case

Contol

Case

Control

CC

CT

TT

CC

CT

TT

AA

AC

CC

AA

AC

CC

Deligezer 2003 (25 )

72

50

9

74

73

14

0,5006

Hur 2006(22 )

13

17

10

80

80

40

0,0184

31

7

2

116

78

6

0,0944

Chen 2006(6 )

2

2

3

72

66

19

0,522

Moon 2007(26 )

43

45

27

144

196

94

0,0779

74

33

8

307

120

7

0,2189

Barbosa 2008(7 )

46

19

2

65

29

6

0,2701

41

23

3

63

32

5

0,7221

Kim 2009(27 )

54

72

26

540

863

297

0,1326

97

49

5

1147

500

53

0,8678

Ismail 2008(28 )

63

67

19

94

66

10

0,722

59

68

22

76

81

13

0,1724

Vahid 2010(23 )

24

11

3

56

37

4

0,4872

12

19

7

39

36

22

0,0211

Jankovic 2011(29 )

17

21

5

6

16

4

0,2247

Lordelo 2012(24 )

15

21

5

74

66

15

0,9594

26

15

0

68

79

8

0,0132

Lordelo 2012(24 )

31

26

7

66

48

4

0,1787

35

28

1

51

64

3

0,0844

Hussein 2012(30 )

28

8

7

180

61

10

0,106

Jakoljevic 2013(31 )

8

29

5

13

33

7

0,057

Dorgham 2014(32 )

8

35

40

48

38

3

0,1649

27

31

26

50

42

5

0,3082

Banescu 2014(33 )

58

68

25

154

116

35

0,0727

67

68

16

149

119

37

0,0868

Rabab M Aly 2014(14 )

30

44

11

45

49

6

0,1192

32

38

15

40

51

9

0 ,199

Korshied 2014(13 )

41

45

11

65

52

13

0,5872

54

37

6

55

65

10

0,1206

P HWE: P value for Hardy-weinberg equilibrium

Only one study (Hur s’ study (22 )) was removed, since the distributions were not in accordance with the HWE, for the C677T polymorphism. Likewise, the distribution of the A1298C genotypes in controls were not in accordance with the WHE in two studies: Vahid(23 ) and Lordelo (24 ) reports. 1362 cases and 4357 controls were found in these studies for MTHFR C677T polymorphism. The allele and variants genotype frequency of each study were listed in Table 2 . In the case group, the range of T allele frequencies was from 16 to 45%. It changed from 17 to 36% for Asian population, from 23 to 33% for Caucasian population and from 16 to 29% for mixed population. The T allele frequency was 45% for African population. In the control group of C677T polymorphism, the allele T frequencies varied from 14 to 38%. In the same way, a total of 1086 cases and 3609 controls were enrolled in these studies for MTHFR A1298C polymorphism. For the case group, the C allele frequencies varied from 11 to 34%. For African population, the C allele frequency was 34%. It changed from 11 to 34%for Asian population, from 18 to 28% for Caucasian population and from 19 to 31% for mixed population. While in the control group the rate of C allele frequency varied from 15 to 30%.

Meta- analysis results :

The meta-analysis of association studies were summarized in Table 3 .
Table 3

Table 3 a. Odds ratio (OR), heterogeneity results and publication bias for the genetic contrasts of MTHFR gene C677T polymorphisms for CML risks.

Model C677T

Ethnicity

Number

Heterogeneity ‘s tests

Association ‘s tests

Publication bias

P-value

OR

CI

P-value

P-value Egger’s test)

Allele contrast (Tvs C)

Overall

17

80,82%

0,0001

1,28

[1.01; 1.63]

0,039721

0,4453

African

1

NA

NA

6,87

[4.27; 11.03]

0

NA

Asian

6

44,68%

0,1076

1,04

[0.89; 1.22]

0,58702

0,0513

Caucasian

5

66,6%

0,0175

0,98

[0.69; 1.39]

0,935452

0,3034

Mixed

5

13,94%

0,3254

1,35

[1.12; 1.63]

0,001918

0,1257

Recessive model (TT vs TC+CC)

Overall

17

63,8%

0,0002

1,67

[1.16; 2.41]

0,005973

0,1311

African

1

NA

NA

26,66

[7.8; 91.14]

1,64E-07

NA

Asian

6

56,57%

0,0421

1,60

[0.97; 2.63]

0,063045

0,0364

Caucasian

5

0%

0,5732

1,14

[0.77; 1.68]

0,508805

0,1149

Mixed

5

24,07%

0,2609

1,78

[1.13; 2.8]

0,012638

0,6376

Dominant model (CC vs TT+TC)

Overall

17

69,79%

0,0001

1,23

[0.94; 1.6]

0,127175

0,4733

African

1

NA

NA

10,97

[4.74; 25.42]

2,25E-08

NA

Asian

6

0

0,5513

0,94

[0.75; 1.18]

0,586297

0,0904

Caucasian

5

68,69%

0,0124

0,95

[0.57; 1.58]

0,842135

0,3761

Mixed

5

0%

0,5631

1,38

[1.08; 1.77]

0,009783

0,105

Homozygote (TT vs CC)

Overall

17

73,57%

0,0001

1,79

[1.13; 2.83]

0,01326

0,1821

African

1

NA

NA

80

[19.89; 321.7]

7E-10

NA

Asian

6

56,79%

0,0411

1,53

[0.89; 2.65]

0,126373

0,0403

Caucasian

5

44,69%

0,1242

1,19

[0.78; 1.8]

0,419753

0,1361

Mixed

5

28,73%

0,23

2,05

[1.28; 3.28]

0,002904

0,5168

Heterozygote (TT vs CC)

Overall

17

51,02%

0,0082

1,10

[0.88; 1.38]

0,397935

0,8322

African

1

NA

NA

5,53

[2.29; 13.29]

0,000136

NA

Asian

6

0%

0,8978

0,84

[0.66; 1.08]

0,171749

0,5167

Caucasian

5

61,23%

0,0354

0,95

[0.59; 1.53]

0,845969

0,4038

Mixed

5

0%

0,8226

1,29

[1.001; 1.68]

0,048527

0,0384

I2 : degree of heterogenity ; OR : Odds Ratio ; IC: confidence interval

By examining the heterogeneity tests ‘results, we took into consideration the random effect model since the p value<0,05 and I²>50% for the C677T and A1298C polymorphisms, except one heterozygous model of the A1298C polymorphism. Overall, we have found a poor association between CML risk and the C677T polymorphism under the allele contrast model (Figure 2 ); recessive model (TT vs. TC+CC) and homozygous model (TT vs. CC). For the dominant model (CC vs. TT+TC) and the heterozygous model (TC vs. CC), the association is not significant.

Figure 2 A. Forest plot of C677T polymorphisms and CML under the allele contrast model

According to the ethnicity, a significant association between CML risk and C677T variant in African population was described under all models (Table 3a ). Moreover, in the overall population, we have found no significant association between the A1298C polymorphism and the CML risk, respectively for the allele contrast, the recessive and the homozygous model (. Subgroup analysis by ethnicity showed a magnitude effect in African population under all models except those heterozygote model (CA vs. AA) whose association was not significant (OR= 1, 37, 95%CI=0, 7071-2,6423, p=0,3527)(Table 3b ).
Table 4

 Table 3 b. Odds ratio (OR), heterogeneity results and publication bias for the genetic contrasts of MTHFR gene A1298C polymorphisms for CML risks.

Model A1298C

Ethnicity

Number

Heterogeneity ‘s tests

Association ‘s tests

Publication bias

P-value

OR

CI

P-value

P-value Egger’s test)

Allele contrast (C vs A)

Overall

12

70,61%

0,0001

1,06

[0.85; 1.33]

0,610745

0,2087

African

1

NA

NA

2,66

[1.72; 4.13]

1,17E-05

NA

Asian

4

53,73%

0,0903

1,08

[0.79; 1.49]

0,616595

0,3436

Caucasian

2

78,63%

0,0305

0,77

[0.37; 1.59]

0,488287

NA

Mixed

5

52,04%

0,0799

0,99

[0.75; 1.31]

0,951556

0,3622

Recessive model (CC vs AC+AA)

Overall

12

58,74%

0,0052

1,51

[0.93; 2.45]

0,097038

0,744

African

1

NA

NA

8,25

[2.99; 22.69]

4,38E-05

NA

Asian

4

56,31%

0,0763

1,54

[0.67; 3.52]

0,305413

0,7443

Caucasian

2

0%

0,3463

0,80

[0.44; 1.48]

0,486417

NA

Mixed

5

0%

0,4084

1,53

[0.97; 2.43]

0,067319

0,1337

Dominant model (AA vs CC+AC)

Overall

12

60,14%

0,0037

0,99

[0.78; 1.27]

0,971503

0,1982

African

1

NA

NA

2,24

[1.22; 4.12]

0,008968

NA

Asian

4

60,22%

0,0565

1,04

[0.68; 1.61]

0,846408

0,5194

Caucasian

2

82,04%

0,0183

0,77

[0.29; 1.99]

0,590829

NA

Mixed

5

38,73%

0,163

0,91

[0.71; 1.16]

0,435625

0,5895

Homozygote (CC vs AA)

Overall

12

58,86%

0,005

1,52

[0.92; 2.51]

0,106747

0,5131

African

1

NA

NA

9,63

[3.32; 27.95]

3,09E-05

NA

Asian

4

44,7%

0,1432

1,65

[0.95; 2.87]

0,073228

0,944

Caucasian

2

32,95%

0,222

0,88

[0.46; 1.66]

0,691687

NA

Mixed

5

25%

0,2548

1,43

[0.88; 2.32]

0,143511

0,1763

Heterozygote (CA vs AA)

Overall

12

46,02%

0,0404

0,94

[0.75; 1.17]

0,585394

0,133

African

1

NA

NA

1,37

[0.71; 2.64]

0,352779

NA

Asian

4

63,73%

0,0407

0,99

[0.61; 1.61]

0,980956

0,5831

Caucasian

2

79,93%

0,0256

0,83

[0.33; 2.08]

0,694699

NA

Mixed

5

8,51%

0,358

0,84

[0.65; 1.09]

0,197205

0,7727

Publication’s bias:

Egger’s test was applied to assess possible publication bias of the included studies. For C677T polymorphism, Table 3a showed publication bias for Asian population under recessive model and homozygote model (TT vs. CC) and for mixed population under heterozygote model (TC vs. CC). The A1298C polymorphism didn’t show any publication bias according to Egger’s test represented on Table 3b . Begg’s Funnel plots was used showing a symmetrical shape for the two polymorphisms (Figure 4 ).

Figure 3. Funnel plot analysis of potential publication biais. A: Funnel plots analysis for publication biais between MTHFR C677Tpolymorphism and CML ; B : Funnel plots analysis for publication biais between MTHFR A1298C polymorphism and CML.

Sensitivity analysis

Sensitivity analyses of both MTHFR C677T and A1298C indicated that no study has significantly influenced the pooled ORs.

DISCUSSION:

In the current meta-analysis, the relationship was explored between the polymorphisms of MTHFR and CML involving 1362 cases and 4357 controls for the C677T and 1086 cases and 3609 controls for the A1298C variant. In the overall population, the prevalence of T allele (for the C677T) and the C allele (for the A1298C) ranged from 16 to 45% and from 11 to 34%, respectively. These frequencies were largely presented in the African population. This finding could explain the significant association that we have found, among other reasons, between the two polymorphisms and the CML risk in the African population. In fact, a poor association was described between the C677T MTHFR polymorphism and CML risk, with the allele contrast model, the recessive and the homozygous model. These results were not consistent with a previous published meta-analysis by Li et al (17 ). The stratification analysis by ethnicities showed a significant association for African population, suggesting a possible role of ethnic differences in the genetic background and environmental factors regarding the C677T polymorphisms and the risk of CML, especially since the T allele frequency varied by ethnicities. Concerning the A1298C polymorphism, no association between for the allele contrast, the recessive and the homozygous models in the overall population was described. Subgroup analysis by ethnicity showed a magnitude effect in African population under all models except that heterozygote model (CA vs. AA) whose association was not significant. These results were not consistent with the last meta-analysis (17 ). Previously, many studies indicated the association between the polymorphisms of the MTHFR gene and CML with inconclusive results. The inconsistent conclusions are due to many reasons leading to the low statistical power. They may be also the result of fundamental differences and heterogeneity between studies like the selection of controls, age distribution and life style factors. Heterogeneity between studies is a critical problem which must be conducted. To avoid the potential heterogeneity, carefully publication search, strict studies inclusion criteria, precise data extraction, and strict statistical analysis were performed in this meta-analysis. First of all, the distributions of the C677T genotypes in controls were not in accordance with the HWE in one study(22 ). In the same way, the distribution of the A1298C genotypes in controls were not in accordance with the WHE in two studies (23, 24 ). So these reports whose P (HWE) < 0, 05 might not be in HWE should be excluded from the meta-analysis. Moreover, high heterogeneities emerged in comparisons between MTHFR C677T and A1298C polymorphisms in overall, Asian and Caucasian populations under different genetic models. Heterogeneities cannot be avoided and may result from selection of the control groups, study design, ethnicity differences and lifestyle factors. Substantial publication bias was found for the C677T polymorphism in Asian population under recessive model, homozygote model (TT vs. CC), and in Mixed population under heterozygote model (TC vs. CC). The A1298C polymorphism didn’t show any publication bias according to Egger’s test. So there is always a certain degree of publication bias, since only published studies were included in this meta-analysis. Non-significant or negative results may be unpublished. Likewise, the results of sensitivity analysis showed that no individual study influenced the pooled ORs, indicating the results of this meta-analysis are stable. It should be noted that the use of only “Pubmed” database may skew our results. So, adding indexed publications in other biomedical databases such as Scopus or Web of Science may prevent publications bias and improve our study’conclusion. Considering the limitations of this meta-analysis, the results should be interpreted with caution.

CONCLUSION:

In conclusion, this meta-analysis suggested poor and no association between C677Tand A1298C polymorphisms respectively, and CML risk. However, due to the limitations of this study, these results should be interpreted with caution and still require future large-scale studies to confirm their accuracy. Moreover, considering that CML is a complex disease with a multifactorial etiology, the development of adult CML might be associated with other factors such us folic acid intake, gene-gene and gene-environment interactions in order to provide more conclusive evidence regarding the genetic susceptibility to adult CML. First author Publication year Ethnicity (country) Polymorphisms studied Cases Controles Number Mean Age (years) Number Mean Age (years) Deligezer 2003(25 ) 2003 Caucasian (Turkey) C677T 131 (F/M= 70/61) 45,9 161 (F/M= 112/48) 39 Hur 2006(22 ) 2006 Asian (Korea) C677T, A1298C 40 (F/M= 13/27) 50 200 (F/M= 72/128 34 Chen 2006(6) 2006 Asian (China) C677T 7 (NA) NA 157 (NA) NA Moon 2007(26 ) 2007 Asian (Korea) C677T, A1298C 115 (F/M= 40/75) 43,8 434 (F/M=238/19) 41,4 Barbosa(7) 2008 Mixed (Brasil) C677T, A1298C 67 (F/M= 30/36) 44 100 (F/M=47/53) 29 Kim 2009(27 ) 2009 Asian (Korea) C677T, A1298C 149 (F/M= 55/94) 50,4 1700 (F/M= 879/821) 52,2 Ismail 2008(28 ) 2009 Mixed (Jordan) C677T, A1298C 149 (NA) NA 170 (NA) NA Vahid 2010(23 ) 2010 Mixed (Iran) C677T, A1298C 38 (F/M= 19/19) 45 97(F/M= 50/47) 44,8 Jankovic 2011(29 ) 2011 Caucasian (Serbia) C677T 43 (NA) NA 26 (NA) NA Lordelo 2012(24 ) 2012 Caucasian C677T, A1298C 41 (NA) NA 155 (NA) NA Lordelo 2012(24 ) 2012 Mixed (Brasil) C677T, A1298C 64 (NA) NA 118 (NA) NA Hussein 2012(30 ) 2012 Asian (India) C677T 43 (NA) 39,5 251 (NA) 41,5 Jakoljevic 2013(31 ) 2012 Caucasian (Serbia) C677T 52 (F/M= 24/28) NA 53 (F/M= 24/30) NA Dorgham 2014(32 ) 2014 African (Algeria) C677T, A1298C 90 (NA) 45,9 100 (NA) 47,3 Banescu 2014(33 ) 2014 Caucasian (Romania) C677T, A1298C 151 (F/M= 65/86) 51 305 (F/M= 179/126) 47 Rabab M Aly 2014(14) 2014 Mixed (Egypt) C677T, A1298C 85 (F/M= 40/45) 46,7 100 (F/M= 49/51) 48,2 Korshied 2014(13 ) 2014 MIxed (Egypt) C677T, A1298C 97 (F/M= 51/46) NA 130 (F/M= 68/62) NA F: female; M: male; NA: not available Study Distribution of C677T MTHFR genotype(n) HWE P value Distribution of A1298 MTHFR genotype(n) HWE P value Case Contol Case Control CC CT TT CC CT TT AA AC CC AA AC CC Deligezer 2003 ( 72 50 9 74 73 14 0,5006 Hur 2006() 13 17 10 80 80 40 0,0184 31 7 2 116 78 6 0,0944 Chen 2006() 2 2 3 72 66 19 0,522 Moon 2007() 43 45 27 144 196 94 0,0779 74 33 8 307 120 7 0,2189 Barbosa 2008() 46 19 2 65 29 6 0,2701 41 23 3 63 32 5 0,7221 Kim 2009() 54 72 26 540 863 297 0,1326 97 49 5 1147 500 53 0,8678 Ismail 2008() 63 67 19 94 66 10 0,722 59 68 22 76 81 13 0,1724 Vahid 2010() 24 11 3 56 37 4 0,4872 12 19 7 39 36 22 0,0211 Jankovic 2011() 17 21 5 6 16 4 0,2247 Lordelo 2012() 15 21 5 74 66 15 0,9594 26 15 0 68 79 8 0,0132 Lordelo 2012() 31 26 7 66 48 4 0,1787 35 28 1 51 64 3 0,0844 Hussein 2012() 28 8 7 180 61 10 0,106 Jakoljevic 2013() 8 29 5 13 33 7 0,057 Dorgham 2014() 8 35 40 48 38 3 0,1649 27 31 26 50 42 5 0,3082 Banescu 2014() 58 68 25 154 116 35 0,0727 67 68 16 149 119 37 0,0868 Rabab M Aly 2014() 30 44 11 45 49 6 0,1192 32 38 15 40 51 9 0 ,199 Korshied 2014() 41 45 11 65 52 13 0,5872 54 37 6 55 65 10 0,1206 P HWE: P value for Hardy-weinberg equilibrium Model C677T Ethnicity Number Heterogeneity ‘s tests Association ‘s tests Publication bias P-value OR CI P-value P-value Egger’s test) Allele contrast (Tvs C) Overall 17 80,82% 0,0001 1,28 [1.01; 1.63] 0,039721 0,4453 African 1 NA NA 6,87 [4.27; 11.03] 0 NA Asian 6 44,68% 0,1076 1,04 [0.89; 1.22] 0,58702 0,0513 Caucasian 5 66,6% 0,0175 0,98 [0.69; 1.39] 0,935452 0,3034 Mixed 5 13,94% 0,3254 1,35 [1.12; 1.63] 0,001918 0,1257 Recessive model (TT vs TC+CC) Overall 17 63,8% 0,0002 1,67 [1.16; 2.41] 0,005973 0,1311 African 1 NA NA 26,66 [7.8; 91.14] 1,64E-07 NA Asian 6 56,57% 0,0421 1,60 [0.97; 2.63] 0,063045 0,0364 Caucasian 5 0% 0,5732 1,14 [0.77; 1.68] 0,508805 0,1149 Mixed 5 24,07% 0,2609 1,78 [1.13; 2.8] 0,012638 0,6376 Dominant model (CC vs TT+TC) Overall 17 69,79% 0,0001 1,23 [0.94; 1.6] 0,127175 0,4733 African 1 NA NA 10,97 [4.74; 25.42] 2,25E-08 NA Asian 6 0 0,5513 0,94 [0.75; 1.18] 0,586297 0,0904 Caucasian 5 68,69% 0,0124 0,95 [0.57; 1.58] 0,842135 0,3761 Mixed 5 0% 0,5631 1,38 [1.08; 1.77] 0,009783 0,105 Homozygote (TT vs CC) Overall 17 73,57% 0,0001 1,79 [1.13; 2.83] 0,01326 0,1821 African 1 NA NA 80 [19.89; 321.7] 7E-10 NA Asian 6 56,79% 0,0411 1,53 [0.89; 2.65] 0,126373 0,0403 Caucasian 5 44,69% 0,1242 1,19 [0.78; 1.8] 0,419753 0,1361 Mixed 5 28,73% 0,23 2,05 [1.28; 3.28] 0,002904 0,5168 Heterozygote (TT vs CC) Overall 17 51,02% 0,0082 1,10 [0.88; 1.38] 0,397935 0,8322 African 1 NA NA 5,53 [2.29; 13.29] 0,000136 NA Asian 6 0% 0,8978 0,84 [0.66; 1.08] 0,171749 0,5167 Caucasian 5 61,23% 0,0354 0,95 [0.59; 1.53] 0,845969 0,4038 Mixed 5 0% 0,8226 1,29 [1.001; 1.68] 0,048527 0,0384 I2 : degree of heterogenity ; OR : Odds Ratio ; IC: confidence interval Model A1298C Ethnicity Number Heterogeneity ‘s tests Association ‘s tests Publication bias P-value OR CI P-value P-value Egger’s test) Allele contrast (C vs A) Overall 12 70,61% 0,0001 1,06 [0.85; 1.33] 0,610745 0,2087 African 1 NA NA 2,66 [1.72; 4.13] 1,17E-05 NA Asian 4 53,73% 0,0903 1,08 [0.79; 1.49] 0,616595 0,3436 Caucasian 2 78,63% 0,0305 0,77 [0.37; 1.59] 0,488287 NA Mixed 5 52,04% 0,0799 0,99 [0.75; 1.31] 0,951556 0,3622 Recessive model (CC vs AC+AA) Overall 12 58,74% 0,0052 1,51 [0.93; 2.45] 0,097038 0,744 African 1 NA NA 8,25 [2.99; 22.69] 4,38E-05 NA Asian 4 56,31% 0,0763 1,54 [0.67; 3.52] 0,305413 0,7443 Caucasian 2 0% 0,3463 0,80 [0.44; 1.48] 0,486417 NA Mixed 5 0% 0,4084 1,53 [0.97; 2.43] 0,067319 0,1337 Dominant model (AA vs CC+AC) Overall 12 60,14% 0,0037 0,99 [0.78; 1.27] 0,971503 0,1982 African 1 NA NA 2,24 [1.22; 4.12] 0,008968 NA Asian 4 60,22% 0,0565 1,04 [0.68; 1.61] 0,846408 0,5194 Caucasian 2 82,04% 0,0183 0,77 [0.29; 1.99] 0,590829 NA Mixed 5 38,73% 0,163 0,91 [0.71; 1.16] 0,435625 0,5895 Homozygote (CC vs AA) Overall 12 58,86% 0,005 1,52 [0.92; 2.51] 0,106747 0,5131 African 1 NA NA 9,63 [3.32; 27.95] 3,09E-05 NA Asian 4 44,7% 0,1432 1,65 [0.95; 2.87] 0,073228 0,944 Caucasian 2 32,95% 0,222 0,88 [0.46; 1.66] 0,691687 NA Mixed 5 25% 0,2548 1,43 [0.88; 2.32] 0,143511 0,1763 Heterozygote (CA vs AA) Overall 12 46,02% 0,0404 0,94 [0.75; 1.17] 0,585394 0,133 African 1 NA NA 1,37 [0.71; 2.64] 0,352779 NA Asian 4 63,73% 0,0407 0,99 [0.61; 1.61] 0,980956 0,5831 Caucasian 2 79,93% 0,0256 0,83 [0.33; 2.08] 0,694699 NA Mixed 5 8,51% 0,358 0,84 [0.65; 1.09] 0,197205 0,7727
  28 in total

1.  [A new method for 5, 10-methylenetetrahydrofolate reductase single nucleotide polymorphisms genotyping used to study susceptibility of hematological malignancy].

Authors:  Bao-An Chen; Ni Jiang; Mei-Ju Ji; Peng Hou; Zu-Hong Lu; Chong Gao; Jia-Hua Ding; Yun-Yu Sun; Jun Wang; Jian Cheng; Gang Zhao
Journal:  Zhongguo Shi Yan Xue Ye Xue Za Zhi       Date:  2006-12

2.  Methylenetetrahydrofolate reductase C677T genetic polymorphisms and risk of leukaemia among the North Indian population.

Authors:  Syed Rizwan Hussain; Hena Naqvi; Syed Tasleem Raza; Faisal Ahmed; Sunil G Babu; Ashutosh Kumar; Zeashan Haider Zaidi; Farzana Mahdi
Journal:  Cancer Epidemiol       Date:  2012-03-20       Impact factor: 2.984

3.  Methylenetetrahydrofolate reductase A1298C genotypes are associated with the risks of acute lymphoblastic leukaemia and chronic myelogenous leukaemia in the Korean population.

Authors:  M Hur; J Y Park; H C Cho; K M Lee; H Y Shin; H I Cho
Journal:  Clin Lab Haematol       Date:  2006-06

4.  MTHFR 677CC/1298CC genotypes are highly associated with chronic myelogenous leukemia: a case-control study in Korea.

Authors:  Hee Won Moon; Tae Young Kim; Bo Ra Oh; Hyun Chung Min; Han Ik Cho; Soo Mee Bang; Jae Hoon Lee; Sung Soo Yoon; Dong Soon Lee
Journal:  Leuk Res       Date:  2006-12-06       Impact factor: 3.156

5.  The methylenetetrahydrofolate reductase (MTHFR) 677 C>T polymorphism increases the risk of developing chronic myeloid leukemia-a case-control study.

Authors:  Claudia Bănescu; Mihaela Iancu; Adrian P Trifa; Ioan Macarie; Delia Dima; Minodora Dobreanu
Journal:  Tumour Biol       Date:  2014-12-16

Review 6.  Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.

Authors:  J Gabert; E Beillard; V H J van der Velden; W Bi; D Grimwade; N Pallisgaard; G Barbany; G Cazzaniga; J M Cayuela; H Cavé; F Pane; J L E Aerts; D De Micheli; X Thirion; V Pradel; M González; S Viehmann; M Malec; G Saglio; J J M van Dongen
Journal:  Leukemia       Date:  2003-12       Impact factor: 11.528

7.  Association between polymorphisms of folate-metabolizing enzymes and hematological malignancies.

Authors:  Hee Nam Kim; Yeo-Kyeoung Kim; Il-Kwon Lee; Deok-Hwan Yang; Je-Jung Lee; Min-Ho Shin; Kyeong-Soo Park; Jin-Su Choi; Moo Rim Park; Deog Yeon Jo; Jong Ho Won; Jae-Yong Kwak; Hyeoung-Joon Kim
Journal:  Leuk Res       Date:  2008-09-06       Impact factor: 3.156

Review 8.  A systematic review and meta-analysis of MTHFR polymorphisms in methotrexate toxicity prediction in pediatric acute lymphoblastic leukemia.

Authors:  E Lopez-Lopez; I Martin-Guerrero; J Ballesteros; A Garcia-Orad
Journal:  Pharmacogenomics J       Date:  2012-10-23       Impact factor: 3.550

9.  Polymorphisms of methylenetetrahydrofolate reductase (MTHFR) and susceptibility to pediatric acute lymphoblastic leukemia in a German study population.

Authors:  Eckart Schnakenberg; Andrea Mehles; Gunnar Cario; Klaus Rehe; Kathrin Seidemann; Brigitte Schlegelberger; Holger A Elsner; Karl H Welte; Martin Schrappe; Martin Stanulla
Journal:  BMC Med Genet       Date:  2005-05-27       Impact factor: 2.103

Review 10.  Chronic Myeloid Leukaemia in The 21st Century.

Authors:  Rachel Frazer; Alexandra E Irvine; Mary Frances McMullin
Journal:  Ulster Med J       Date:  2007-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.